Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Accounts Payables: 2022-2024

Historic Accounts Payables for Immunocore Holdings (IMCR) over the last 3 years, with Dec 2024 value amounting to $25.1 million.

  • Immunocore Holdings' Accounts Payables rose 16.40% to $23.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.0 million, marking a year-over-year increase of 16.40%. This contributed to the annual value of $25.1 million for FY2024, which is 41.03% up from last year.
  • Per Immunocore Holdings' latest filing, its Accounts Payables stood at $25.1 million for FY2024, which was up 41.03% from $17.8 million recorded in FY2023.
  • Immunocore Holdings' Accounts Payables' 5-year high stood at $25.1 million during FY2024, with a 5-year trough of $14.4 million in FY2022.
  • Over the past 3 years, Immunocore Holdings' median Accounts Payables value was $17.8 million (recorded in 2023), while the average stood at $19.1 million.
  • Data for Immunocore Holdings' Accounts Payables shows a peak YoY surged of 41.03% (in 2024) over the last 5 years.
  • Over the past 3 years, Immunocore Holdings' Accounts Payables (Yearly) stood at $14.4 million in 2022, then grew by 23.17% to $17.8 million in 2023, then spiked by 41.03% to $25.1 million in 2024.